Consensus of experts from the French Society of Geriatrics and Gerontology on the management of heart failure in very old subjects.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 03 07 2020
revised: 26 11 2020
accepted: 01 12 2020
pubmed: 19 1 2021
medline: 30 4 2021
entrez: 18 1 2021
Statut: ppublish

Résumé

The prevalence of heart failure increases with age. In France, the 1-year mortality rate is 35% in subjects aged 80-89 years with heart failure, and 50% after the age of 90 years. In octogenarians, heart failure is associated with high rates of cardiovascular and non-cardiovascular events, and is one of the main causes of hospitalization and disability. The prevalence of frailty increases in elderly subjects with heart failure, and the co-occurrence of heart failure and frailty increases the risk of mortality in patients with heart failure. In the elderly, the presence of frailty must be evaluated using a comprehensive geriatric assessment to manage geriatric syndromes, such as cognitive disorders, malnutrition, falls, depression, polypharmacy, disability and social isolation. The objective of heart failure therapy in octogenarians is to reduce symptoms, mortality and hospitalizations, but also to improve quality of life. In the absence of specific studies involving very old subjects, most recommendations are extrapolated from evidence-based data from younger populations. Overall, the epidemiological studies in patients with heart failure aged>80 years highlight the underprescription of recommended drugs. This underprescription may be related to comorbidity, a fear of side-effects and the lack of specific recommendations for drug prescription in heart failure with preserved ejection fraction, which is common in this very old population. The benefit/risk ratio related to heart failure treatment and comorbidity should be carefully weighed and reassessed on a regular basis. Consideration of disease prognosis according to factors that predict mortality can help to better define the care plan and promote palliative and supportive care when needed.

Identifiants

pubmed: 33455889
pii: S1875-2136(20)30264-3
doi: 10.1016/j.acvd.2020.12.001
pii:
doi:

Substances chimiques

Cardiovascular Agents 0

Types de publication

Journal Article Practice Guideline Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-259

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Olivier Hanon (O)

Service de gériatrie, hôpital Broca, AP-HP, 75013 Paris, France; EA 4468, gérontopôle d'Île-de-France, université de Paris, 75013 Paris, France. Electronic address: olivier.hanon@aphp.fr.

Joël Belmin (J)

Service de gériatrie, hôpital Charles-Foix, 94200 Ivry-sur-Seine, France; Faculté de médecine, Sorbonne université, 75103 Paris, France.

Athanase Benetos (A)

Service de médecine interne gériatrique, CHRU plurithématiques-Nancy, 54035 Nancy, France; UMR_S 1116, Inserm, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.

Philippe Chassagne (P)

Service de médecine interne gériatrique, CHU de Rouen, 76000 Rouen, France.

Laure De Decker (L)

Service de gérontologie clinique, CHU de Nantes, 44093 Nantes, France.

Claude Jeandel (C)

Centre Antonin-Balmès, CHU de Montpellier, 34090 Montpellier, France.

Pierre Krolak-Salmon (P)

Institut du vieillissement, hôpital des Charpennes, hospices civils de Lyon, 69002 Lyon, France; Inserm 1048, université de Lyon, 69675 Bron, France.

Fati Nourhashemi (F)

Gérontopôle, CHU de Toulouse, 31059 Toulouse, France; Inserm 1027, 31000 Toulouse, France.

Marc Paccalin (M)

Pôle de Gériatrie, CHU La Milétrie, 86021 Poitiers, France; CIC 1402, Inserm, centre hospitalier universitaire de Poitiers, université de Poitiers, 86000 Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH